GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Spring Pharmaceutical Group Inc (OTCPK:CYIG) » Definitions » Enterprise Value

Spring Pharmaceutical Group (Spring Pharmaceutical Group) Enterprise Value : $1.50 Mil (As of May. 05, 2024)


View and export this data going back to . Start your Free Trial

What is Spring Pharmaceutical Group Enterprise Value?

Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Spring Pharmaceutical Group's Enterprise Value is $1.50 Mil. Spring Pharmaceutical Group's EBIT for the trailing twelve months (TTM) ended in Mar. 2019 was $19.15 Mil. Therefore, Spring Pharmaceutical Group's EV-to-EBIT ratio for today is 0.08.

EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Spring Pharmaceutical Group's Enterprise Value is $1.50 Mil. Spring Pharmaceutical Group's EBITDA for the trailing twelve months (TTM) ended in Mar. 2019 was $22.90 Mil. Therefore, Spring Pharmaceutical Group's EV-to-EBITDA ratio for today is 0.07.

EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Spring Pharmaceutical Group's Enterprise Value is $1.50 Mil. Spring Pharmaceutical Group's Revenue for the trailing twelve months (TTM) ended in Mar. 2019 was $69.79 Mil. Therefore, Spring Pharmaceutical Group's EV-to-Revenue ratio for today is 0.02.


Spring Pharmaceutical Group Enterprise Value Historical Data

The historical data trend for Spring Pharmaceutical Group's Enterprise Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Spring Pharmaceutical Group Enterprise Value Chart

Spring Pharmaceutical Group Annual Data
Trend Mar10 Mar11 Mar12 Mar13 Mar14 Mar15 Mar16 Mar17 Mar18 Mar19
Enterprise Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.07 -1.67 5.84 -1.43 7.77

Spring Pharmaceutical Group Quarterly Data
Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19
Enterprise Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.43 -0.05 -0.55 -10.39 7.77

Competitive Comparison of Spring Pharmaceutical Group's Enterprise Value

For the Drug Manufacturers - Specialty & Generic subindustry, Spring Pharmaceutical Group's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Spring Pharmaceutical Group's Enterprise Value Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Spring Pharmaceutical Group's Enterprise Value distribution charts can be found below:

* The bar in red indicates where Spring Pharmaceutical Group's Enterprise Value falls into.



Spring Pharmaceutical Group Enterprise Value Calculation

Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

Spring Pharmaceutical Group's Enterprise Value for the fiscal year that ended in Mar. 2019 is calculated as

Spring Pharmaceutical Group's Enterprise Value for the quarter that ended in Mar. 2019 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Spring Pharmaceutical Group  (OTCPK:CYIG) Enterprise Value Explanation

When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.

If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.

The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.

For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.

Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.

1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.

Spring Pharmaceutical Group's EV-to-EBIT for today is

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=1.500/19.148
=0.08

Spring Pharmaceutical Group's current Enterprise Value is $1.50 Mil.
Spring Pharmaceutical Group's EBIT for the trailing twelve months (TTM) ended in Mar. 2019 adds up the quarterly data reported by the company within the most recent 12 months, which was $19.15 Mil.

2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.

Spring Pharmaceutical Group's EV-to-EBITDA for today is:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA(TTM)
=1.500/22.903
=0.07

Spring Pharmaceutical Group's current Enterprise Value is $1.50 Mil.
Spring Pharmaceutical Group's EBITDA for the trailing twelve months (TTM) ended in Mar. 2019 adds up the quarterly data reported by the company within the most recent 12 months, which was $22.90 Mil.

3. EV-to-Revenue is calculated as Enterprise Value divided by its Revenue.

Spring Pharmaceutical Group's EV-to-Revenue for today is:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=1.500/69.793
=0.02

Spring Pharmaceutical Group's current Enterprise Value is $1.50 Mil.
Spring Pharmaceutical Group's Revenue for the trailing twelve months (TTM) ended in Mar. 2019 adds up the quarterly data reported by the company within the most recent 12 months, which was $69.79 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Spring Pharmaceutical Group Enterprise Value Related Terms

Thank you for viewing the detailed overview of Spring Pharmaceutical Group's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Spring Pharmaceutical Group (Spring Pharmaceutical Group) Business Description

Traded in Other Exchanges
N/A
Address
No. 11, Quanxing Road, Sishui County, Shandong Province, Jinan, CHN, 273200
Spring Pharmaceutical Group Inc is a health care company. The company is engaged in the developing, manufacturing and selling innovative traditional Chinese medicines made from panax ginseng leaves extract, developing acer truncatum bunge planting, processing and selling acer truncatum bunge seed oils in the PRC. Some of its product includes Vitality Source Capsule (24 capsules); Vitality Source Capsules (36 capsules); Millet cattle drinking music and others.